公开(公告)号：US20230174983A1

公开(公告)日：2023-06-08

申请号：US17921809

申请日：2021-07-13

申请人： NANJING GENEFRIEND-BIOTECH INC.

发明人： Yifan DAI ,  Haiyuan YANG

IPC分类号： C12N15/113 ,  C12N15/85 ,  A01K67/027 ,  C12N9/10 ,  C12N9/22

CPC分类号： C12N15/113 ,  C12N15/85 ,  A01K67/0276 ,  C12N9/1051 ,  C12N9/22 ,  A01K2217/075 ,  A01K2227/108 ,  A01K2267/03 ,  A01K2267/0387 ,  C12N2310/10

摘要： Provided is gRNA specifically targeting β4GalNT2 gene. The gRNA specifically binds to the nucleotide sequence shown in any one of SEQ ID NOs. 1 and 2. Also provided are an animal model constructed using the gRNA, and an application thereof in the field of biomedicine.

公开(公告)号：US20230172172A1

公开(公告)日：2023-06-08

申请号：US18159414

申请日：2023-01-25

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Andrew J. Murphy ,  Alexander O. Mujica ,  Ka-Man Venus Lai ,  Sokol Haxhinasto ,  Zaruhi Hovhannisyan

IPC分类号： A01K67/027 ,  C07K16/24 ,  C07K16/28 ,  C12N15/85

CPC分类号： A01K67/0278 ,  C07K16/244 ,  C07K16/2866 ,  C12N15/8509 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2227/105 ,  C07K2317/24 ,  C07K2317/76 ,  C12N2015/8527 ,  A01K2267/0368 ,  A01K2217/15

摘要： This disclosure relates to genetically modified rodent animals and rodent models of human diseases. More specifically, this disclosure relates to genetically modified rodents whose genome comprises a humanized Il1rl2 gene (coding for the IL1rl2 subunit of the IL-36R protein) and human IL-36α, β and γ ligand genes. The genetically modified rodents disclosed herein display enhanced skin and intestinal inflammation as a preclinical model of psoriasis and IBD, respectively, and serve as a rodent model of human DITRA disease.

公开(公告)号：US20230165901A1

公开(公告)日：2023-06-01

申请号：US17901424

申请日：2022-09-01

申请人： Mesoblast, Inc.

发明人： Piroska Elizabeth Rakoczy

IPC分类号： A61K35/28 ,  A01K67/027 ,  C12N5/0775

CPC分类号： A61K35/28 ,  A01K67/027 ,  C12N5/0663 ,  A01K2207/30 ,  A01K2227/105 ,  A01K2267/0375 ,  A01K2267/0393 ,  A61K2035/124

摘要： The present invention relates to methods of treating or preventing angiogenesis-related diseases by the administration of stem cells and/or progeny cells thereof.

公开(公告)号：US20230159660A1

公开(公告)日：2023-05-25

申请号：US17947884

申请日：2022-09-19

申请人： Kymab Limited

发明人： Allan Bradley ,  E-Chiang Lee ,  Wei Wang ,  Dominik Spensberger ,  Hui Liu ,  Jasper Clube ,  Qi Liang

IPC分类号： C07K16/46 ,  C12N15/85 ,  C07K16/12 ,  C07K16/18 ,  A01K67/027

CPC分类号： C07K16/461 ,  C12N15/8509 ,  C07K16/1239 ,  C07K16/18 ,  A01K67/0278 ,  C07K16/462 ,  C07H21/04

摘要： The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.

公开(公告)号：US11638744B2

公开(公告)日：2023-05-02

申请号：US15757452

申请日：2016-09-02

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Shiro Shibayama ,  Hiroshi Arima ,  Takuya Simbo

IPC分类号： A61K38/17 ,  C07K14/705 ,  A61K45/06 ,  A61K38/00 ,  A61K45/00 ,  A01K67/027 ,  A61P35/02 ,  C07K16/28 ,  A61K39/00 ,  A61K39/395

摘要： A method for suppression of progress of, suppression of recurrence of and/or treatment of cancer, by administering an Allergin-1 antagonist in a therapy of a cancer patient with insufficient therapeutic efficacy by a tumor immunotherapeutic agent, or a cancer therapy in combination with an anti-cancer drug.

公开(公告)号：US11634730B2

公开(公告)日：2023-04-25

申请号：US16385383

申请日：2019-04-16

申请人： The Regents of the University of California ,  University of Vienna ,  Emmanuelle Charpentier

发明人： Jennifer A. Doudna ,  Martin Jinek ,  Krzysztof Chylinski ,  Emmanuelle Charpentier

IPC分类号： C12N15/10 ,  A61K38/46 ,  C12N15/11 ,  C12N15/113 ,  C12N15/63 ,  C12N15/70 ,  C12N15/74 ,  C12N15/90 ,  C12Q1/686 ,  C12N9/22 ,  A01H6/46 ,  A01K67/027 ,  H01L21/205 ,  H01L33/00 ,  H01L21/02 ,  A61K48/00

摘要： The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.

公开(公告)号：US11622547B2

公开(公告)日：2023-04-11

申请号：US16894302

申请日：2020-06-05

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Qing Fang ,  Chia-Jen Siao ,  Dan Chalothorn ,  KehDih Lai ,  Leah Sabin ,  Rachel Sattler ,  Brian Zambrowicz ,  Lori Morton

IPC分类号： A01K67/027 ,  A61K49/00 ,  C07K14/76 ,  C12N15/85

摘要： Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized albumin (ALB) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized albumin locus express a human albumin protein or a chimeric albumin protein, fragments of which are from human albumin. Methods are provided for using such non-human animals comprising a humanized albumin locus to assess in vivo efficacy of human-albumin-targeting reagents such as nuclease agents designed to target human albumin.

公开(公告)号：US11617356B2

公开(公告)日：2023-04-04

申请号：US15770811

申请日：2016-10-26

申请人： PÉCSI TUDOMÁNYEGYETEM

发明人： Péter Balogh ,  Dávid Ernszt ,  Tamás Kovács

IPC分类号： A01K67/027 ,  C12N5/09

摘要： The invention relates to a new, spontaneous mouse lymphoma cell line displaying CD19, B220, MHC II, surface IgG2a/kappa chain and MAC-1, which is negative for CD5, animal models of B-cell lymphoma based on said cell line and methods for assessing lymphoma propagation and lymphoma expansion based on said cell line.

公开(公告)号：US20230102342A1

公开(公告)日：2023-03-30

申请号：US17759539

申请日：2021-03-23

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Meghan Drummond Samuelson ,  Jeffery Haines ,  Charleen Hunt ,  Guochun Gong ,  Brian Zambrowicz

IPC分类号： A01K67/027 ,  C07K14/47

摘要： Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TTR locus comprising a V30M mutation and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TTR locus express a human TTR protein or a chimeric TTR protein, fragments of which are from human TTR. Methods are provided for using such non-human animals comprising a humanized TTR locus to assess in vivo efficacy of human-TTR-targeting reagents such as nuclease agents designed to target human TTR.

公开(公告)号：US11612151B2

公开(公告)日：2023-03-28

申请号：US16729852

申请日：2019-12-30

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Lynn Macdonald ,  Cagan Gurer ,  Karolina A. Hosiawa ,  Sean Stevens ,  Andrew J. Murphy

IPC分类号： A01K67/027 ,  C07K16/46 ,  C12N9/64 ,  C07K16/28

摘要： Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin λ light chain variable domain.